MabVax Therapeutics Lines Up $3.7M Ch. 11 Asset Sale

By Jeff Montgomery (May 6, 2019, 9:45 PM EDT) -- After a last-minute negotiating flurry, biotech firm MabVax Therapeutics Holdings secured tentative approval Monday for the $3.7 million sale of many of its remaining assets while retaining litigation rights against alleged fraudsters who crippled the company....

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.

  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!


Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!